FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Cancer Pain

Abstral (fentanyl sublingual tablets) (by ProStrakan), Approved January 2011
For the treatment of breakthrough cancer pain in opioid-tolerant patients

Lazanda (fentanyl citrate) nasal spray (by Archimedes), Approved June 2011
For the management of breakthrough cancer pain

Onsolis (fentanyl buccal) (by BioDelivery Sciences), Approved July 2009
For the management of breakthrough cancer pain

Quadramet (Samarium Sm 153 Lexidronam Injection) (by DuPont Merck Pharmaceutical Company), Approved March 1997
Treatment for pain associated with bone cancer

Subsys (fentanyl sublingual spray) (by Insys Therapeutics), Approved January of 2012
For the treatment of breakthrough cancer pain

Cancer Prevention

Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (by GlaxoSmithKline), Approved October 2009
For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18

Inform HER-2/neu breast cancer test (by Oncor), Approved January 1998
Treatment for breast cancer prediction

Self-examination breast pad (by Inventive Products), Approved on December 22, 1995
Self-examination breast pad

Cancer/Tumors

Subsys (fentanyl sublingual spray) (by Insys Therapeutics), Approved January of 2012
For the treatment of breakthrough cancer pain

Candidemia/Candidiasis

Oravig (miconazole) (by Strativa Pharmaceuticals), Approved April 2010
oropharyngeal candidiasis

Canker Sores

Aphthasol (by Block Drug Company), Approved December 1997
Treatment for canker sores

Apthasol (Amlexanox) (by Access Pharmaceuticals), Approved May 1996
Treatment for canker sores

Carrington patch (by Carrington Laboratories), Approved May 1996
Treatment for canker sores

Cardiac Ischemia

ReoPro (by Centocor Ortho Biotech), Approved November 1997
Treatment for cardiac ischemic complications

Zontivity (vorapaxar) (by Merck), Approved May 2014
For the reduction of thrombotic cardiovascular events

Cardiovascular Abnormalities

Kynamro (mipomersen sodium) (by Genzyme), Approved January 2013
For the treatment of homozygous familial hypercholesterolemia

Praluent (alirocumab) (by Sanofi Aventis), Approved July 2015
For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease

Cataracts

Omidria (phenylephrine and ketorolac injection) (by Omeros), Approved June 2014
For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain

Cervical Cancer

Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (by GlaxoSmithKline), Approved October 2009
For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18

Chickenpox (Varicella Zoster Infection)

VariZIG, Varicella Zoster Immune Globulin (Human) (by Cangene), Approved January 2013
For the post-exposure prophylaxis of varicella zoster (chickenpox)

Chronic Bronchitis

Biaxin XL (clarithromycin extended-release tablets) (by Abbott Laboratories), Approved March 2000
For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis

Cedax (ceftibuten) (by Schering-Plough), Approved December 1995
Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis

Raxar (grepafloxacin) (by GlaxoSmithKline), Approved November 1997
Treatment for chronic bronchitis

Zagam (sparfloxacin) tablets (by Rhone Poulenc Rorer), Approved January 1997
Treatment for community-acquired pneumonia (CAP) and chronic bronchitis

Chronic Diarrhea

Fulyzaq (crofelemer) (by Salix Pharmaceuticals), Approved December 2012
For the treatment of non-infectious diarrhea in adults with HIV/AIDS

Viberzi (eluxadoline) (by Actavis), Approved May 2015
For the treatment of irritable bowel syndrome with diarrhea

Xifaxan (rifaximin) (by Salix Pharmaceuticals), Approved May 2015
For the treatment of irritable bowel syndrome with diarrhea

Chronic Lymphocytic Leukemia

Arzerra (ofatumumab) (by GlaxoSmithKline), Approved October 2009
For the treatment of chronic lymphocytic leukemia

Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) (by Orphan Medical), Approved October 1996
Treatment of meningeal leukemia or lymphocytic lymphoma

Gazyva (obinutuzumab) (by Genentech), Approved October of 2013
For the treatment of previously untreated chronic lymphocytic leukemia

Imbruvica (ibrutinib) (by Pharmacyclics), Approved February 2014
For the treatment of chronic lymphocytic leukemia

Imbruvica (ibrutinib) (by Pharmacyclics), Approved November of 2013
For the treatment of mantle cell lymphoma

Treanda (bendamustine hydrochloride) (by Cephalon), Approved October 2008
For the treatment of Chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma

Zydelig (idelalisib) (by Gilead), Approved July 2014
For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma

Chronic Myeloid Leukemia

Bosulif (bosutinib) (by Pfizer), Approved September 2012
For the treatment of Ph+ chronic myelogenous leukemia

Gleevec (imatinib mesylate) (by Novartis), Approved May 2001
Oral therapy for the treatment of chronic myeloid leukemia

Iclusig (ponatinib) (by Ariad Pharmaceuticals), Approved December 2012
For the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia

Sprycel (dasatinib) (by Bristol-Myers Squibb), Approved June 2006
For the treatment of imatinib-resistant chronic myeloid leukemia

Synribo (omacetaxine mepesuccinate) (by Teva Pharmaceutical), Approved October 2012
For the treatment of chronic or accelerated phase chronic myeloid leukemia

Chronic Obstructive Lung Disease

Incruse Ellipta (umeclidinium inhalation powder) (by GlaxoSmithKline), Approved May 2014
For the treatment of chronic obstructive pulmonary disease

Tudorza Pressair (aclidinium bromide inhalation powder) (by Forest Laboratories), Approved July 2012
For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease

Chronic Pain

Anexsia (by Mallinckrodt Group), Approved August 1996
Treatment for chronic pain

Avinza (morphine sulfate) (by Elan Pharmaceuticals), Approved March 2002
Extended release capsule for the relief of pain requiring continuous, around-the-clock therapy

Butrans (buprenorphine) Transdermal System (by Purdue Pharma), Approved July 2010
moderate to severe chronic pain

Kadian (by Purepac Pharmaceutical), Approved July 1996
Treatment for chronic moderate to severe pain

Movantik (naloxegol) (by AstraZeneca), Approved September 2014
For the treatment of opiod-induced constipation in adults with chronic non-cancer pain

Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets (by Purdue Pharma), Approved July 2014
For the management of severe chronic pain

UltraJect (by Mallinckrodt Group), Approved August 1996
Treatment for chronic pain

Clostridium Difficile-Associated Diarrhea

Dificid (fidaxomicin) (by Optimer Pharmaceuticals), Approved May 2011
For the treatment of Clostridium difficile-associated diarrhea

Cold Sores (Herpes Labialis Infections)

Sitavig (acyclovir) buccal tablets (by BioAlliance Pharma), Approved April 2013
For the treatment of recurrent herpes labialis in adults

Colorectal Cancer

Avastin (bevacizumab) (by Genentech), Approved February 2004
For the treatment of metastatic carcinoma of the colon or rectum

Campostar (by Pharmacia & Upjohn), Approved June 1996
Treatment for metastatic colorectal cancer

CEA-Scan (by Immunomedics), Approved April 1996
Diagnostic imaging product for colorectal cancer

Erbitux (cetuximab) (by Imclone, Bristol-Myers Squibb), Approved February 2004
For the treatment of EGFR-expressing, metastatic colorectal cancer

Stivarga (regorafenib) (by Bayer HealthCare Pharmaceuticals), Approved September 2012
For the treatment of previously treated patients with metastatic colorectal cancer

Vectibix (panitumumab) (by Amgen), Approved September 2006
For the treatment of colorectal cancer

Zaltrap (ziv-aflibercept) (by Sanofi-aventis), Approved August 2012
For the treatment of metastatic colorectal cancer

Common Cold

Atrovent (ipratropium bromide) (by Boehringer Ingelheim), Approved January 1996
Treatment for runny nose due to allergies and the common cold

Children's Advil (pediatric ibuprofen) (by Whitehall-Robins Healthcare), Approved July 1996
Treatment of fever and minor aches and pains

Children's Motrin Cold (by McNeil Consumer Products), Approved August 2000
For temporary relief of the common cold

Tavist (clemastine fumarate) (by Novartis), Approved March 2001
Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold

Tavist (clemastine fumarate) (by Sandoz Pharmaceuticals), Approved November 1996
Treatment for cold symptoms

Conjunctivitis, Bacterial

Grastek (Timothy Grass Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis

Ragwitek (Short Ragweed Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of short ragweed pollen-induced allergic rhinitis

Zymaxid (gatifloxacin ophthalmic solution) (by Allergan), Approved May 2010
For the treatment of bacterial conjunctivitis

Constipation

Linzess (linaclotide) (by Forest Labs and Ironwood Pharmaceuticals), Approved August 2012
For the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

Movantik (naloxegol) (by AstraZeneca), Approved September 2014
For the treatment of opiod-induced constipation in adults with chronic non-cancer pain

Contraception

Alesse (100 mcg levonorgestrel/20 mcg ethinyl estradiol tablets) (by Wyeth), Approved April 1997
Treatment for the prevention of pregnancy

ella (ulipristal acetate) (by HRA Pharma), Approved August 2010
For the emergency prevention of contraception

Estrostep (norethindrone acetate and ethinyl estradiol) (by Warner-Lambert), Approved March 1997
Treatment for oral contraception

Estrostep (norethindrone acetate and ethinyl estradiol) (by Parke-Davis), Approved October 1996
Treatment for birth control

Lo Minastrin, (norethindrone acetate, ethinyl estradiol, ferrous fumarate) (by Warner Chilcott), Approved July 2013
For the prevention of pregnancy

Mircette (by Organon), Approved April 1998
Oral contraceptive

Mirena (levonorgestrel-releasing intrauterine system) (by Berlex Laboratories), Approved December 2000
Hormone-releasing system for intrauterine contraception

Natazia (estradiol valerate + dienogest) (by Bayer), Approved May 2010
For the prevention of contraception

NuvaRing (by Organon), Approved October 2001
Monthly vaginal ring for birth control

Ortho Evra (by Ortho-McNeil Pharmaceutical), Approved November 2001
Transdermal patch for contraception

Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) (by Teva Pharmaceutical), Approved April 2013
For the prevention of conception

Seasonale, Lo Seasonale, Seasonique (ethinylestradiol + levonorgestrel) (by Duramed Pharmaceuticals), Approved September 2003
For the prevention of contraception

Trivora-21 and Trivora-28 (by Watson Pharmaceuticals), Approved December 1997
Generic equivalents of levonorgestrel and ethinyl estradiol

Yasmin (drospirenone/ethinyl estradiol) (by Berlex Laboratories), Approved May 2001
Oral contraceptive

COPD (Chronic Obstructive Pulmonary Disease)

Anoro Ellipta (umeclidinium and vilanterol inhalation powder) (by GlaxoSmithKline), Approved December of 2013
For the maintenance treatment of chronic obstructive pulmonary disease

Arcapta (indacaterol maleate inhalation powder) (by Novartis), Approved July 2011
For the treatment of airflow obstruction resulting from chronic obstructive pulmonary disease

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) (by GlaxoSmithKline), Approved May 2013
For the treatment of chronic obstructive pulmonary disease

Daliresp (roflumilast) (by Forest Pharmaceuticals), Approved February 2011
For the treatment of chronic obstructive pulmonary disease

DuoNeb (albuterol sulfate and ipratropium bromide) (by Dey Laboratories), Approved March 2001
For the treatment of bronchospasm associated with COPD

Foradil Aerolizer (formoterol fumarate inhalation powder) (by Novartis), Approved February 2001 (asthma, bronchospasm); September 2001 (COPD)
Bronchodilator for COPD, asthma and bronchospasm

Incruse Ellipta (umeclidinium inhalation powder) (by GlaxoSmithKline), Approved May 2014
For the treatment of chronic obstructive pulmonary disease

Spiriva HandiHaler (tiotropium bromide) (by Boehringer Ingelheim), Approved February 2004
For the treatment of bronchospasm associated with chronic obstructive pulmonary disease

Stiolto Respimat (tiotropium bromide and olodaterol) (by Boehringer Ingelheim), Approved May 2015
For the maintenance of chronic obstructive pulmonary disease

Striverdi Respimat (olodaterol) (by Boehringer Ingelheim), Approved July 2014
For the treatment of chronic obstructive pulmonary disease

Tudorza Pressair (aclidinium bromide inhalation powder) (by Forest Laboratories), Approved July 2012
For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease

Coronary Artery Disease

Kengreal (cangrelor) (by The Medicines Company), Approved June 2015
For reducing periprocedural thrombotic events

Crohn's Disease

Cimzia (certolizumab pegol) (by UCB), Approved April 2008
For the treatment of Crohn’s disease

Entocort EC (budesonide) (by AstraZeneca), Approved October 2001
Capsules for the treatment of mild-to-moderate, active Crohn's disease

Entyvio (vedolizumab) (by Millenium Pharmaceuticals), Approved May of 2014
For the treatment of adults with ulcerative colitis and Crohn's disease

Tysabri (natalizumab) (by Biogen IDEC), Approved January 2008
For the maintenance treatment of moderate to severe Crohn’s disease

Cushing's Disease

Korlym (mifepristone) (by Corcept Therapeutics), Approved February 2012
For the control of hyperglycemia in adults with endogenous Cushing’s syndrome

Signifor (pasireotide diaspartate) (by Novartis), Approved December of 2012
For the treatment of Cushing's disease

Cutaneous T-Cell Lymphoma

Istodax (romidepsin) (by Gloucester Pharmaceuticals), Approved November 2009
For the treatment of cutaneous T-cell lymphoma

Valchlor (mechlorethamine) gel (by Ceptaris Therapeutics), Approved August 2013
For the treatment of Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma

Cystic Fibrosis

Cayston (aztreonam for inhalation solution) (by Gilead), Approved February 2010
For the treatment of cystic fibrosis patients with Pseudomonas aeruginosa

Kalydeco (ivacaftor) (by Vertex Pharmaceuticals), Approved January of 2012
For the treatment of cystic fibrosis with the G551D mutation in the CFTR gene

Orkambi (lumacaftor and ivacaftor) (by Vertex Pharmaceuticals), Approved July 2015
For the treatment of cystic fibrosis

Pulmozyme (dornase alfa) (by Genentech), Approved December 1996
Treatment for cystic fibrosis patients with advanced disease

Pulmozyme (dornase alfa) (by Genentech), Approved March 1998
Treatment for cystic fibrosis

Tobi (by PathoGenesis), Approved December 1997
Treatment for cystic fibrosis

Ultresa (pancrelipase) delayed-release capsules (by Aptalis Pharma), Approved March 2012
For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions

Zenpep (pancrelipase) (by Eurand), Approved August 2009
For the treatment of pancreatic insufficiency due to cystic fibrosis or other conditions

Cytomegalovirus (CMV) Retinitis

Oral Cytovene (by Roche), Approved December 1996
Treatment for the prevention of cytomegalovirus (CMV)

Vistide (cidofovir) (by Gilead), Approved June 1996
Treatment for cytomegalovirus (CMV) retinitis

Vitrasert Implant (by Chiron), Approved March 1996
Drug delivery system for the treatment of cytomegalovirus

Vitravene Injection (by Isis Pharmaceuticals), Approved August 1998
Treatment for CMV in AIDS patients